Les publications des Arcad group

Cohen R, Raeisi M, Chibaudel B, Yoshino T, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, André T, de Gramont A. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer. 2024 Mar, 199:113537 DOI: 10.1016/j.ejca.2024.113537
Disponible sur :  https://www.ejcancer.com/article/S0959-8049(24)00013-3/abstract

Karapetis CS, Liu H, Sorich MJ, Pederson LD, Van Cutsem E, Maughan T, Douillard JY, O’Callaghan CJ, Jonker D, Bokemeyer C, Sobrero A, Cremolini C, Chibaudel B, Zalcberg J, Adams R, Buyse M, Peeters M, Yoshino T, de Gramont A, Shi Q. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. Br J Cancer. 2024 Feb 24, [Epub ahead of print] PMID: 38402342 DOI: 10.1038/s41416-024-02604-y
Disponible sur : https://www.nature.com/articles/s41416-024-02604-y 

Takeda Y, Misumi T, Bando H, Suzuki M, Wakabayashi M, Oki E, Yamazaki K, Kakeji Y, Shitara K, Terashima M, Raeisi M, Maehara Y, Ohtsu A, Andre T, De Gramont A, Shi Q, Yoshino T. ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow ESMO Gastrointestinal Oncology, Volume 2, 2023, 100007, ISSN 2949-8198
Disponible sur : https://www.esmogastro.org/article/S2949-8198(23)00008-0/fulltext

Yoshino T, Shi Q, Misumi T, Bando H, Wakabayashi M, Raeisi M, Andre T, de Gramont A. A synthetic control arm for refractory metastatic colorectal cancer: the no placebo initiative. Nat Med 2023 Oct, 29 (10):2389-2390 PMID: 37507606 DOI: 10.1038/s41591-023-02488-0
Disponible sur : https://www.nature.com/articles/s41591-023-02488-0

Ou FS, Ahn DH, Dixon JG, Grothey A, Lou Y, Kasi PM, Hubbard JM, Van Cutsem E, Saltz LB, Schmoll HJ, Goldberg RM, Venook AP, Hoff P, Douillard JY, Hecht JR, Hurwitz H, Punt CJA, Koopman M, Bokemeyer C, Fuchs CS, Diaz-Rubio E, Tebbutt NC, Cremolini C, Kabbinavar FF, Bekaii-Saab T, Chibaudel B, Yoshino T, Zalcberg J, Adams RA, de Gramont A, Shi Q. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database. Cancers (Basel). 2023 Aug 15, 15 (16) PMID: 37627145 PMCID: 10452983 DOI: 10.3390/cancers15164117
Disponible sur : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452983/

Margalit O, Harmsen WS, Shacham-Shmueli E, Voss MM, Boursi B, Wagner AD, Cohen R, Olswold CL, Saltz LB, Goldstein DA, Hurwitz H, Tebbutt NC, Kabbinavar FF, Adams RA, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, de Gramont A, Shi Q, Lenz HJ. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database. Eur J Cancer. 2023 Jan, 178:162-170 Epub 2022 Nov 02 PMID: 36446161 DOI: 10.1016/j.ejca.2022.10.022
Disponible sur : https://www.ejcancer.com/article/S0959-8049(22)01325-9/fulltext

Franko J, Yin J#, Adams RA, Zalcberg J, Fiskum J, Van Cutsem E, Goldberg RM, Hurwitz H, Bokemeyer C, Kabbinavar F, Curtis A, Meyers J, Chibaudel B, Yoshino T, de Gramont A, Shi Q, ARCAD collaborators. Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD database. Eur J Cancer. 2022 Aug 19, 174:142-152 [Epub ahead of print] PMID: 35994794 DOI: 10.1016/j.ejca.2022.07.021
Disponible sur : https://www.ejcancer.com/article/S0959-8049(22)00445-2/abstract

McCleary NJ, Harmsen WS, Haakenstad E, Cleary JM, Meyerhardt JA, Zalcberg J, Adams R, Grothey A, Sobrero AF, Van Cutsem E, Goldberg RM, Peeters M, Tabernero Seymour M, Saltz LB, Giantonio BJ, Arnold D, Rothenberg ML, Koopman M, Schmoll H-J, Pitot HC, Hoff PM, Tebbutt N, Masi G, Souglakos J, Bokemeyer C, Heinemann V, Yoshino T, Chibaudel B, MD, deGramont A, Qian Shi Q, Lichtman SM, Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials,  JNCI Cancer Spectrum, Volume 6, Issue 2, April 2022, pkac014
Disponible sur :  https://doi.org/10.1093/jncics/pkac014 

Papamichael D, Lopes GS, Olswold CL, Douillard J-Y, Adams RA, Maughan RS, Van Cutsem E, Venook AP, Lenz H-J, Heinemann V, Kaplan R, Bokemeyer C, Chibaudel B, Grothey A, Yoshino T, Zalcberg J, De Gramont A, Shi Q. Efficacy of anti-EGFR agents in RAS Wildtype metastatic colorectal cancer patients ≥ 70 years. Eur J Cancer. 2022 Jan 13, 163:1-15 [Epub ahead of print] PMID: 35033994 DOI: 10.1016/j.ejca.2021.12.007
Disponible sur : https://linkinghub.elsevier.com/retrieve/pii/S0959804921012624

Goldberg RM, Adams R, Buyse M, Eng C, Grothey A, Andre T, Sobrero AF, Lichtman SM, Benson AB, Punt CJA, Maughan T, Burzykowski T, Sommeijer D, Saad ED, Shi Q, Coart E, Chibaudel B, Koopman M, Schmoll HJ, Yoshino T, Taieb J, Tebbutt NC, Zalcberg J, Tabernero J, Van Cutsem E, Matheson A, de Gramont A. Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. J Natl Cancer Inst. 2021 Dec 4 Epub 2021 Dec 04 PMID: 34865086 DOI: 10.1093/jnci/djab218
Disponible sur : https://academic.oup.com/jnci/article-abstract/114/6/819/6449449?redirectedFrom=fulltext&login=false

Yin J, Dawood S, Cohen R, Meyers J, Zalcberg J, Yoshino T, Seymour M, Maughan T, Saltz L, Van Cutsem E, Venook A, Schmoll HJ, Goldberg R, Hoff P, Hecht JR, Hurwitz H, Punt C, Diaz Rubio E, Koopman M, Cremolini C, Heinemann V, Tournigard C, Bokemeyer C, Fuchs C, Tebbutt N, Souglakos J, Doulliard JY, Kabbinavar F, Chibaudel B, de Gramont A, Shi Q, Grothey A, Adams R.  Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Ther Adv Med Oncol. 2021; 13:17588359211020547 Epub 2021 June 30 PMID: 34262614 PMCID: 8252342 DOI: 10.1177/17588359211020547
Disponible sur : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252342/

Yin J, Cohen R, Jin Z, Liu H, Pederson L, Adams R, Grothey A, Maughan TS, Venook A, Van Cutsem E, Punt C, Koopman M, Falcone A, Tebbutt NC, Seymour MT, Bokemeyer C, Rubio ED, Kaplan R, Heinemann V, Chibaudel B, Yoshino T, Zalcberg J, Andre T, De Gramont A, Shi Q, Lenz HJ. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 Jun 1 Epub 2021 June 01 PMID: 34061178 DOI: 0.1093/jnci/djab112
Disponible sur : https://academic.oup.com/jnci/article/113/12/1705/6290718?login=false

Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS, Van Cutsem E, Venook A, Douillard JY, Heinemann V, Punt CJA, Falcone A, Bokemeyer C, Kaplan R, Lenz HJ, Koopman M, Yoshino T, Zalcberg J, Grothey A, de Gramont A, Shi Q, Andre T.  BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. J Natl Cancer Inst. 2021 Mar 18 [Epub ahead of print] PMID: 33734401 DOI: 10.1093/jnci/djab042
Disponible sur : https://academic.oup.com/jnci/article/113/10/1386/6178005?login=false

Lopes GS, Tournigand C, Olswold CL, Cohen R, Kempf E, Saltz L, Goldberg RM, Hurwitz H, Fuchs C, de Gramont A, Shi Q.  Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. Clin Trials. 2020 Oct 1; 1740774520959313 Epub 2020 Oct 01 PMID: 32998522 DOI: 10.1177/1740774520959313
Disponible sur : https://journals.sagepub.com/doi/10.1177/1740774520959313

Gulhati P, Yin J, Pederson L, Schmoll HJ, Hoff P, Douillard JY, Hecht JR, Tournigand C, Tebbut N, Chibaudel B, De Gramont A, Shi Q, Overman MJ.  Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients with Elevated CEA. J Natl Cancer Inst. 2020 Mar 19 [Epub ahead of print] PMID: 32191317 DOI: 10.1093/jnci/djaa020
Disponible sur : https://academic.oup.com/jnci/article/112/11/1127/5810087?login=false

Burzykowski T, Coart E, Saad ED, Shi Q, Sommeijer DW, Bokemeyer C, Diaz-Rubio E, Douillard JY, Falcone A, Fuchs CS, Goldberg RM, Hecht JR, Hoff PM, Hurwitz H, Kabbinavar FF, Koopman M, Maughan TS, Punt CJA, Saltz L, Schmoll HJ, Seymour MT, Tebbutt NC, Tournigand C, Van Cutsem E, de Gramont A, Zalcberg JR, Buyse M, Aide et Recherche en Cancerologie Digestive Group.  Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Netw Open. 2019 Sep 4; 2 (9):e1911750 PMID: 31539075 DOI: 10.1001/jamanetworkopen.2019.11750
Disponible sur : https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2751555

Salem ME, Yin J, Weinberg BA, Renfro LA, Pederson LD, Maughan TS, Adams RA, Van Cutsem E, Falcone A, Tebbutt NC, Seymour MT, Diaz-Rubio E, Aranda E, Bokemeyer C, Heinemann V, Wasan H, de Gramont A, Grothey A, Shi Q, Sargent DJ, Marshall JL.  Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. Eur J Cancer. 2018 Nov; 103:205-213 Epub 2018 Sept 27 PMID: 30268921 DOI: 10.1016/j.ejca.2018.08.020
Disponible sur : https://www.ejcancer.com/article/S0959-8049(18)31340-6/abstract

Goey KKH, Sorbye H, Glimelius B, Adams RA, Andre T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Diaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.  Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 Sep; 100:35-45 Epub 2018 June 22 PMID: 29936065 DOI: 10.1016/j.ejca.2018.05.010
Disponible sur : https://www.ejcancer.com/article/S0959-8049(18)30850-5/abstract

Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR, Fondation Aide et Recherche en Cancerologie Digestive Group.  Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2018 June; 110 (6):638-648 2017 Dec 18 [Epub ahead of print] PMID: 29267900 DOI: 10.1093/jnci/djx253
Disponible sur : https://academic.oup.com/jnci/article/110/6/638/4757465?login=false

van Rooijen KL, Shi Q, Goey KKH, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent DJ, Punt CJA, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. Eur J Cancer. 2018 Jan 17; 91:99-106 [Epub ahead of print] PMID: 29353165 DOI: 10.1016/j.ejca.2017.12.014
Disponible sur : https://linkinghub.elsevier.com/retrieve/pii/S0959804917314934

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol. 2017 Apr 18
Disponible sur : https://linkinghub.elsevier.com/retrieve/pii/S0923753419352287

ARCAD Clinical Trials Program, Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database. J Clin Oncol 2017 Jun 10; 35 (17):1929-1937 Epub 2017 Apr 17 PMID:28414610 DOI:10.1200/JCO.2016.71.5771
Disponible sur : https://ascopubs.org/doi/10.1200/JCO.2016.71.5771

Bleiberg H, Decoster G, de Gramont A, Rougier P, Sobrero A, Benson A, Chibaudel B, Douillard JY, Eng C, Fuchs C, Fujii M, Labianca R, Larsen AK, Mithchell E, Schmool HJ, Sprumont D, Zalcberg J. A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD group. Annals of Oncology 0:922-930, 2017 doi:10.1093/annonc/mdx050
Disponible sur : https://linkinghub.elsevier.com/retrieve/pii/S092375341932023X

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone Alfredo, Chibaudel B, Heinemann V, Moen J, De Gramount Aimery, Sargent DJ, Grothey A, for the Analysis and Research in Cancers of the Digestive System (ARCAD) group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomized trials from the analysis and research in cancers of the digestive system (ARCAD) database. Lancet Oncol 2016 Dec; 17 (12):1709-1719 Epub 2016 Oct 12 PMID: 27743922 DOI: 10.1016/S1470-2045(16)30500-9.
Disponible sur : https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30500-9/abstract

Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJ, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ. Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J Clin Oncol. 2016 Jan 10;34(2):144-50. doi: 10.1200/JCO.2015.61.6441. Epub 2015 Oct 26.  PMID:  26503203
Disponible sur : https://ascopubs.org/doi/10.1200/JCO.2015.61.6441

de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J,  de Gramont  A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nature Reviews Clinical Oncology 2015;12:197–212 doi:10.1038/nrclinonc.2014.202
Disponible sur : https://www.nature.com/articles/nrclinonc.2014.202

Shi Q, De Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams RA, Saltz L, Goldberg RM, Punt CJA, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Diaz-Rubio E, Porschen R, Tebbutt NC, Fuchs CS, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse ME, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. Epub  2014 Nov 10. DOI: 10.1200/JCO.2014.56.5887
Disponible sur : https://ascopubs.org/doi/10.1200/JCO.2014.56.5887

Lieu C, Renfro LA, de Gramont A, Maughan TS, Seymour MT, Saltz L, Goldberg RM, Sargent DJ, Eckhardt SG, Eng C. Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD clinical trials program. J Clin Oncol.  2014 Sep 20;32(27):2975-2982. DOI: 10.1200/JCO.2013.54.9329
Disponible sur : https://ascopubs.org/doi/10.1200/JCO.2013.54.9329

Sargent DJ, Buyse M, Matheson A, Goldberg RM, de Gramont, ARCAD Clinical. The ARCAD clinical trials program: an update and invitation.  Oncologist. 2012; 17(2):188-91. Epub 2012 Feb 02.  PMID:22302228. PMCID:3286167. DOI:10.1634/theoncologist.2011-0332.
Disponible sur : https://academic.oup.com/oncolo/article/17/2/188/6403318?login=false

Buyse M, Michiels S, Sargent DJ, Grothey A,  Matheson A & de Gramont A. Integrating biomarkers in clinical trials. Expert Rev. 2011;11(2): 171–182
Disponible sur : https://www.tandfonline.com/doi/full/10.1586/erm.10.120

Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, Allegra CJ, Goldberg RM, de Gramont A. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy–an Aide et Recherche en Cancerologie Digestive Group Study.  J Clin Oncol. 2011 Nov 1; 29(31):4199-204. Epub 2011 Oct 03.  PMID:21969501. DOI:10.1200/JCO.2011.35.5867.
Disponible sur : https://ascopubs.org/doi/10.1200/JCO.2011.35.5867

Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points – the challenge of statistical validation.  Nature Reviews Clinical Oncology 2010; 7:309-317. doi:10.1038/nrclinonc.2010.43
Disponible sur : https://www.nature.com/articles/nrclinonc.2010.43

de Gramont, Haller DG, Sargent DJ, Tabernero J, Matheson A, Schilsky RL. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 2010 Feb 1; 28(4):527-30. Epub 2009 Oct 19. PMID:19841311. DOI:10.1200/JCO.2009.25.2544.
Disponible sur : https://ascopubs.org/doi/10.1200/JCO.2009.25.2544